TY - JOUR
T1 - Physical activity for depression among the chronically Ill
T2 - Results from older diabetics in the Irish longitudinal study on ageing
AU - Laird, Eamon
AU - Herring, Matthew P.
AU - Carson, Brian P.
AU - Woods, Catherine B.
AU - Walsh, Cathal
AU - Kenny, Rose Anne
AU - Rasmussen, Charlotte Lund
N1 - Publisher Copyright:
© 2023
PY - 2023/8
Y1 - 2023/8
N2 - Among chronically-ill older adults, the benefits of moderate-to-vigorous physical activity (MVPA) are established. Comorbid depressive symptoms and Major Depression are prevalent among the chronically-ill, but how different doses of MVPA may protect against depression remains understudied. Thus, using 10 years of data from The Irish Longitudinal Study on Ageing, we quantified longitudinal associations between MVPA doses and depressive symptoms and Major Depression among chronically-ill older adults living with type 2 diabetes (T2DM). Continuous MVPA (MET.min.week−1), three dose and five dose MVPA categories were examined. Depressive symptoms and Major Depression were measured using the center for Epidemiological Studies Depression and the Composite International Diagnostic Interview for Major Depressive Episode. Negative binomial regression and logistic models, adjusted for covariates, quantified associations across time. Among the 2,262 participants, those adhering to the WHO guidelines of 600-<1,200 MET.min.week−1 had 28% lower odds of Major Depression compared to those not achieving the guidelines (OR: 0.72; 95%CI: 0.53–0.98). For depressive symptoms, a higher MVPA dose was required with a 13% (IRR: 0.87; 95%CI: 0.82–0.93) lower rate of symptoms among those exceeding recommendations (1200-<2,400 MET.min.week−1). Interventions should focus on enhancing achievability of and compliance with these MVPA doses among the chronically-ill, including T2DM, to protect against depression.
AB - Among chronically-ill older adults, the benefits of moderate-to-vigorous physical activity (MVPA) are established. Comorbid depressive symptoms and Major Depression are prevalent among the chronically-ill, but how different doses of MVPA may protect against depression remains understudied. Thus, using 10 years of data from The Irish Longitudinal Study on Ageing, we quantified longitudinal associations between MVPA doses and depressive symptoms and Major Depression among chronically-ill older adults living with type 2 diabetes (T2DM). Continuous MVPA (MET.min.week−1), three dose and five dose MVPA categories were examined. Depressive symptoms and Major Depression were measured using the center for Epidemiological Studies Depression and the Composite International Diagnostic Interview for Major Depressive Episode. Negative binomial regression and logistic models, adjusted for covariates, quantified associations across time. Among the 2,262 participants, those adhering to the WHO guidelines of 600-<1,200 MET.min.week−1 had 28% lower odds of Major Depression compared to those not achieving the guidelines (OR: 0.72; 95%CI: 0.53–0.98). For depressive symptoms, a higher MVPA dose was required with a 13% (IRR: 0.87; 95%CI: 0.82–0.93) lower rate of symptoms among those exceeding recommendations (1200-<2,400 MET.min.week−1). Interventions should focus on enhancing achievability of and compliance with these MVPA doses among the chronically-ill, including T2DM, to protect against depression.
KW - Depression
KW - Dose response
KW - Older adults
KW - Physical activity
KW - Type 2 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85163304979&partnerID=8YFLogxK
U2 - 10.1016/j.psychres.2023.115274
DO - 10.1016/j.psychres.2023.115274
M3 - Article
C2 - 37270867
AN - SCOPUS:85163304979
SN - 0165-1781
VL - 326
SP - -
JO - Psychiatry Research
JF - Psychiatry Research
M1 - 115274
ER -